Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT6A | Q92794 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 2/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | ACLY | P53396 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | CASP6 | P55212 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2009835 | 0.90 | KAT6A (0.35) | KAT6AGAAPKMALDH1A1MAPT | |
| SCHEMBL2006900 | 0.89 | KAT6A (0.38) | KAT6AGAAMAPTKMT2AAKR1C3 | |
| SCHEMBL2007967 | 0.86 | ALDH1A1 (0.38) | KAT6AGAAPKMALDH1A1MAPK1 | |
| SCHEMBL2008888 | 0.85 | GAA (0.37) | KAT6AGAAPKMALDH1A1MAPT | |
| SCHEMBL2008660 | 0.84 | HTT (0.34) | KAT6AGAAMAPTKMT2AAKR1C3 | |
| SCHEMBL2007834 | 0.84 | KAT6A (0.35) | KAT6AGAAALDH1A1MAPTKMT2A | |
| SCHEMBL2008403 | 0.83 | KAT6A (0.37) | KAT6AGAAMAPTAKR1C3L3MBTL1 | |
| SCHEMBL2006932 | 0.83 | AKR1C3 (0.37) | KAT6AGAAPKMALDH1A1MAPK1 | |
| SCHEMBL2005053 | 0.81 | GAA (0.35) | KAT6AGAAMAPTKMT2AAKR1C3 | |
| SCHEMBL2006956 | 0.81 | KAT6A (0.37) | KAT6AGAAALDH1A1MAPTAKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1864976-B1 | PROPANE-1,3-DION DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2012-10-10 | — | — | EP | disclosed |
| US-7960562-B2 | Propane-1,3-dione derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2011-06-14 | — | — | US | disclosed |
| US-20090181964-A1 | Propane-1,3-Dione Derivative or Salt Thereof | ASTELLAS PHARMA INC. | 2009-07-16 | — | — | US | disclosed |
| EP-1864976-A1 | PROPANE-1,3-DION DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2007-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181964-A1 | Propane-1,3-Dione Derivative or Salt Thereof | GNRHR, KISS1R, FSHR | KAT6A 3899/4885GAA 3409/4885PKM 2226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.